Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
New angiogenesis research from University of Texas, M. D. Anderson Cancer Center outlined
April 10th, 2007
Investigators publish new data in the report "Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Clinical trials of antiangiogenic agents used alone for advanced malignancy have been disappointing but preclinical studies suggest that the addition of radiation therapy could improve antitumor efficacy. To test the hypothesis that antiangiogenic therapy combined with radiation therapy can overcome the limitations of antiangiogenic monotherapy, we studied the effects of endostatin combined with radiation on the growth and vascularization of A431 human epidermoid carcinomas growing intramuscularly in the legs of mice. Mice...
Source: Drug Law Weekly (2007-04-10)
|
|
Advertisement |
|
|
|
